http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics reports Q2 results, pociredir trial data
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
-
Fulcrum reports positive Phase 1b trial results for sickle cell drug
-
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
-
Fulcrum Therapeutics to present sickle cell drug trial results
-
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
-
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics to Participate in Upcoming May Conferences
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
-
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
-
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
-
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
Fulcrum Therapeutics to Participate in Upcoming December Conferences
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
-
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
-
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics (FULC) Reports Topline Results from Phase 3 REACH Trial of Losmapimod
-
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
-
Fulcrum Therapeutics to Participate in Upcoming September Conferences
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics Inc. (FULC) Appoints Isabel Kalofonos as Chief Commercial Officer, Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
-
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
-
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
-
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
-
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
-
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
-
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
-
Fulcrum Therapeutics to Participate in Upcoming May Conferences
-
Fulcrum Therapeutics Inc. (FULC) Announces Publication of Results from Phase 2b Trial of Losmapimod
-
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
-
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
-
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics (FULC) Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
-
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
